v3.25.2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Research and development revenue $ 5,065 $ 7,478 $ 11,772 $ 13,804
Cost of revenue (2,775) (4,164) (6,314) (7,545)
Gross profit 2,290 3,314 5,458 6,259
Operating costs and expenses:        
General and administrative 4,413 5,756 8,477 10,844
Total operating costs and expenses 4,413 5,756 8,477 10,844
Operating loss (2,123) (2,442) (3,019) (4,585)
Other income (expense):        
Net interest (expense) income (277) (6) (297) 8
Borrowing related costs (124) (699) (705) (975)
Change in fair value of warrant liability (5,449) 348 (1,196) 368
Change in fair value of notes payable (167) 220 (101)
Foreign exchange transaction loss, net (14) (9) (22) (25)
Other income (expenses), including transactions costs 180 (668)
Total other income (expense), net (5,864) (353) (2,000) (1,393)
Loss before income taxes (7,987) (2,795) (5,019) (5,978)
Income tax provision 19 (69) (52) (91)
Net loss $ (7,968) $ (2,864) $ (5,071) $ (6,069)
Net loss per share of common stock        
Basic (in Dollars per share) $ (0.31) $ (0.16) $ (0.21) $ (0.36)
Diluted (in Dollars per share) $ (0.31) $ (0.16) $ (0.21) $ (0.36)
Weighted average common shares outstanding        
Basic (in Shares) 25,421,560 17,598,357 24,409,550 17,079,328
Diluted (in Shares) 25,421,560 17,598,357 24,409,550 17,079,328
Other comprehensive loss:        
Foreign currency translation adjustments $ 32 $ 49 $ (2)
Total comprehensive loss $ (7,936) $ (2,864) $ (5,022) $ (6,071)